B Rehermann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Immune responses in hepatitis B virus infection
    Barbara Rehermann
    Liver Diseases Section, NIDDK, National Institutes of Health, HHS, Bethesda, Maryland 20892, USA
    Semin Liver Dis 23:21-38. 2003
  2. ncbi Hepatitis C virus infection: when silence is deception
    Vito Racanelli
    Liver Diseases Section, NIDDK, National Institutes of Health, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    Trends Immunol 24:456-64. 2003
  3. doi Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Nat Med 19:859-68. 2013
  4. ncbi Immunology of hepatitis B virus and hepatitis C virus infection
    Barbara Rehermann
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B16, 10 Center Drive, Bethesda, MD 20892, USA
    Nat Rev Immunol 5:215-29. 2005
  5. pmc Private aspects of heterologous immunity
    Barbara Rehermann
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 201:667-70. 2005
  6. ncbi Immunological techniques in viral hepatitis
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch NIDDK, National Institutes of Health, DHHS, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    J Hepatol 46:508-20. 2007
  7. ncbi Interaction between the hepatitis C virus and the immune system
    B Rehermann
    Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Liver Dis 20:127-41. 2000
  8. pmc Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH DHHS, Bethesda, MD 20892, USA
    J Clin Invest 119:1745-54. 2009
  9. doi The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    R Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Aliment Pharmacol Ther 33:559-65. 2011
  10. pmc Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells
    H Wedemeyer
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20982, USA
    J Virol 75:11392-400. 2001

Collaborators

Detail Information

Publications48

  1. ncbi Immune responses in hepatitis B virus infection
    Barbara Rehermann
    Liver Diseases Section, NIDDK, National Institutes of Health, HHS, Bethesda, Maryland 20892, USA
    Semin Liver Dis 23:21-38. 2003
    ..This review summarizes the immune response in acute, self-limited and chronic hepatitis B; its differential effects on viral replication and liver injury; and prospects for immunotherapy...
  2. ncbi Hepatitis C virus infection: when silence is deception
    Vito Racanelli
    Liver Diseases Section, NIDDK, National Institutes of Health, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    Trends Immunol 24:456-64. 2003
    ....
  3. doi Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Nat Med 19:859-68. 2013
    ....
  4. ncbi Immunology of hepatitis B virus and hepatitis C virus infection
    Barbara Rehermann
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B16, 10 Center Drive, Bethesda, MD 20892, USA
    Nat Rev Immunol 5:215-29. 2005
    ..This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies...
  5. pmc Private aspects of heterologous immunity
    Barbara Rehermann
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 201:667-70. 2005
    ..Private T cell receptor specificities of these preexisting memory T cell populations influence both disease severity and outcome of subsequent, unrelated virus infections...
  6. ncbi Immunological techniques in viral hepatitis
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch NIDDK, National Institutes of Health, DHHS, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    J Hepatol 46:508-20. 2007
    ..Our aim is to highlight topics and issues that were supported by general agreement and those that were controversial, as well as to provide suggestions for future work...
  7. ncbi Interaction between the hepatitis C virus and the immune system
    B Rehermann
    Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Liver Dis 20:127-41. 2000
    ....
  8. pmc Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH DHHS, Bethesda, MD 20892, USA
    J Clin Invest 119:1745-54. 2009
    ..This review discusses the clinical, virological, and immunological features of acute and chronic hepatitis C and the role of the immune response in spontaneous and treatment-induced HCV clearance...
  9. doi The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes
    R Loomba
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Aliment Pharmacol Ther 33:559-65. 2011
    ..Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined...
  10. pmc Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells
    H Wedemeyer
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20982, USA
    J Virol 75:11392-400. 2001
    ..These results exemplify that host responses to an infectious agent are influenced by cross-reactive memory cells induced by past exposure to heterologous viruses, which could have important consequences for vaccine development...
  11. pmc Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge
    Marian E Major
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institute of Diabetes and Digestive and Kidney Diseases NIH, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6586-95. 2002
    ..These observations have encouraging implications for the development of a vaccine for HCV...
  12. ncbi Hepatitis C vaccines: Inducing and challenging memory T cells
    Masaaki Shiina
    Immunology Section, Liver Diseases Branch NIDDK, National Institutes of Health, DHHS, Bethesda, MD, USA
    Hepatology 43:1395-8. 2006
    ....
  13. ncbi Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health, DHHS, Bethesda, Maryland 20892, USA
    Semin Liver Dis 27:152-60. 2007
    ..These endogenous mechanisms and potential avenues to revert them are the subject of this review...
  14. doi Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver
    Eui Cheol Shin
    Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 27:985-90. 2007
    ..This mechanism may contribute to the high effectiveness of type I IFN-based therapies if administered early during acute HCV infection...
  15. pmc Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees
    Michelina Nascimbeni
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:4781-93. 2003
    ..The rate of HCV clearance following reexposure depends on the cellular immune response, the quality and quantity of which may vary among chimpanzees that recovered from HCV infection...
  16. ncbi Cellular immune responses to the hepatitis B virus polymerase
    Eishiro Mizukoshi
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Immunol 173:5863-71. 2004
    ..These newly described HBV polymerase epitopes could be a valuable component of a therapeutic vaccine for a large and ethnically diverse patient population...
  17. ncbi Effects of antiviral therapy on the cellular immune response in acute hepatitis C
    Fareed Rahman
    Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 40:87-97. 2004
    ..In conclusion, a sustained response to antiviral therapy was not associated with a lasting enhancement of HCV-specific T-cell responsiveness in the blood...
  18. pmc Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C
    Tobias Manigold
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4424-32. 2006
    ..This result suggests that HCV infection alters the population of Foxp3(+)CD4(+)CD25(+) T(Reg) cells...
  19. ncbi Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure?
    Tobias Manigold
    Liver Diseases Section, NIDDK, National Institutes of Health, DHHS, Bethesda, MD, USA
    Hepatology 37:707-10. 2003
  20. pmc Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV
    Eishiro Mizukoshi
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda 20892, USA
    J Infect Dis 198:203-12. 2008
    ..To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years)...
  21. pmc The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection
    Eui Cheol Shin
    Immunology Section, LDB, NIDDK, NIH, Bethesda, MD 20892 1800, USA
    J Virol 82:9782-8. 2008
    ..Thus, HCV-specific CD8 T-cell responses in the blood are valid markers for intrahepatic T-cell activity...
  22. ncbi Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity
    Vito Racanelli
    Liver Diseases Section, Digestive Diseases Branch, NIDDK, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    Immunity 20:47-58. 2004
    ..The findings are relevant for the rational design of vaccines against noncytopathic pathogens like HCV...
  23. ncbi Hepatitis C virus and the threshold of natural killer cell inhibition
    Golo Ahlenstiel
    Liver Diseases Section, NIDDK, National Institutes of Health, DHHS, Bethesda, MD, USA
    Hepatology 41:675-7. 2005
  24. pmc Liver-directed gamma interferon gene delivery in chronic hepatitis C
    Eui Cheol Shin
    Liver Diseases Branch, NIDDK, National Institutes of Health, DHHS, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    J Virol 79:13412-20. 2005
    ..In conclusion, liver-directed IFN-gamma gene delivery resulted in HCV-specific and nonspecific activation of cellular immune responses but did not result in effective control of HCV replication...
  25. ncbi Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus
    M Thomson
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1800, USA
    Gastroenterology 121:1226-33. 2001
    ..In addition, a limited virus-specific immunity may contribute to HCV persistence...
  26. pmc Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection
    Eui Cheol Shin
    Immunology Section and Liver Diseases Branch, NIDDK, NIH, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Clin Invest 116:3006-14. 2006
    ..This mechanism may contribute to the high effectiveness (95%) of type I IFN-based therapies if administered early during HCV infection...
  27. pmc Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates
    Sook Hyang Jeong
    Liver Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 78:6995-7003. 2004
    ..Our results suggest that HCV-LP is a potent immunogen to induce HCV-specific humoral and cellular immune responses in primates and may be a promising approach to develop novel preventive and therapeutic modalities...
  28. pmc Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies
    Eishiro Mizukoshi
    Liver Diseases Section, NIDDK, National Institutes of Health Laboratory of Hepatitis Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 76:6093-103. 2002
    ..These results are relevant for the design and evaluation of vaccines in chimpanzees that can now be selected according to the most frequent human MHC haplotypes...
  29. pmc The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity
    Michael Thomson
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:862-70. 2003
    ....
  30. doi Analysis of HCV-specific T cells by flow cytometry
    Masaaki Shiina
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 510:415-26. 2009
    ..Here, we provide both an overview of available techniques as well as standard protocols that have proven valuable in the assessment of HCV-specific T-cell responses...
  31. pmc Natural killer cell function is intact after direct exposure to infectious hepatitis C virions
    Joo Chun Yoon
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 49:12-21. 2009
    ..Without direct inhibition by HCV, NK cells may become activated by cytokines in acute HCV infection and contribute to infection outcome and disease pathogenesis...
  32. pmc Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner
    Golo Ahlenstiel
    Immunology Section, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 138:325-35.e1-2. 2010
    ....
  33. ncbi Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function
    Masaaki Shiina
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:385-95. 2008
    ..5.1 cells were infected with HCVcc. In contrast to HCVcc, vaccinia virus inhibited maturation and TNF-alpha expression of myeloid DC as well as maturation and IL-6 and IL-10 production of monocyte-derived DC...
  34. doi Determination of HCV-specific T-cell activity
    Joo Chun Yoon
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 510:403-13. 2009
    ....
  35. pmc Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins
    J Satoi
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1800, USA
    J Virol 75:12121-7. 2001
    ..The HCV transgenic mice can be induced by DNA immunization to generate anti-HCV antibodies and anticore CTLs. However, they are tolerant at the CTL level against the E2 protein despite DNA immunization...
  36. ncbi Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model
    H Wedemeyer
    Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-1800, USA
    Gastroenterology 121:1158-66. 2001
    ..CONCLUSIONS: Oral immunization with attenuated Salmonella typhimurium as a carrier for HCV DNA induces long-lasting T-cell responses...
  37. pmc Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses
    Golo Ahlenstiel
    Immunology Section, Liver Diseases Branch, NIDDK, NIH, Bethesda, Maryland 20892 1800, USA
    J Clin Invest 118:1017-26. 2008
    ..These results provide functional evidence for differential NK cell responsiveness depending on KIR/HLA genotype and may provide useful insights into differential innate immune responsiveness to viral infections such as IAV...
  38. ncbi Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
    Heiner Wedemeyer
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:3447-58. 2002
    ..Thus, the defective functions of HCV-specific CD8+ T cells might contribute to viral persistence in chronically infected patients, and knowledge on their reversibility may facilitate the development of immunotherapeutic vaccines...
  39. ncbi Determination of hepatitis B virus-specific CD8+ T-cell activity in the liver
    Michelina Nascimbeni
    Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Med 96:65-83. 2004
  40. ncbi Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions
    Michelina Nascimbeni
    Liver Diseases Section, DDB, NIDDK, National Institutes of Health, DHHS 10 Center Drive, Bldg 10, Room 9B16, Bethesda, MD 20892 1800, USA
    Blood 104:478-86. 2004
    ....
  41. ncbi Acute hepatitis C: a multifaceted disease
    Theo Heller
    Liver Diseases Branch, NIDDK, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Semin Liver Dis 25:7-17. 2005
    ....
  42. ncbi Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo
    Thomas von Hahn
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10021, USA
    Gastroenterology 132:667-78. 2007
    ....
  43. ncbi Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 89 Rue de 1 institut, B 1330 Rixensart, Belgium
    Vaccine 23:2591-601. 2005
    ..AS02A can be considered as a useful adjuvant that strongly enhances the cellular and humoral responses of subunit protein vaccines...
  44. ncbi The liver as an immunological organ
    Vito Racanelli
    Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
    Hepatology 43:S54-62. 2006
    ....
  45. pmc Hepatitis C virus mutation affects proteasomal epitope processing
    Ulrike Seifert
    Institute of Biochemistry, Charite, Humboldt University, Berlin, Germany
    J Clin Invest 114:250-9. 2004
    ....
  46. pmc High levels of subgenomic HCV plasma RNA in immunosilent infections
    Flavien Bernardin
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Virology 365:446-56. 2007
    ..The absence of immunological pressure and a high viral load may therefore promote the emergence of truncated HCV subgenomic replicons in vivo...
  47. ncbi Chronic HCV infection and the clonality of intrahepatic T cells
    Michelina Nascimbeni
    J Hepatol 38:677-80. 2003